The results of the FinHer study published in the New England Journal of Medicine

Marko Suojanen (marko.suojanen a, Mar 15th 2006

Researchers affiliated with the FinHer Study have reported that Taxotere® (docetaxel) is superior to Navelbine® (vinorelbine) when given in addition to 5-FU, epirubicin and cyclophosphamide (FEC) for adjuvant therapy of women with axillary-node positive or high-risk node negative breast cancer. They also demonstrated the effectiveness of Herceptin (trastuzumab) for treatment of HER-2/neu positive breast cancer. The details of this study appeared in the February 16, 2006, issue of the New England Journal of Medicine and were presented at the 2005 San Antonio Breast Cancer Symposium.